Back to Sites University of Florida Jacksonville Site Number 5051 Address University of Florida Jacksonville 653-1 West 8th Street LRC 3rd Floor Jacksonville, FL 32209 United States of America IMPAACT Members at this Site Joseph Mims CAB Member Ana Alvarez Co-Investigator Bernadette Belgado Co-Investigator Feroz Bhinde Co-Investigator Peggy Borum Co-Investigator Denise Darracott Co-Investigator Carol Fulton Co-Investigator Nizar Maraqa Co-Investigator Ayesha Mirza Co-Investigator Elaine Poon Co-Investigator Saniyyah Mahmoudi CRS Coordinator Mobeen Rathore CRS Leader Michele Burke CRS Staff Angela Monroe CRS Staff Laura Armas-Kolostroubis Investigator Renette Dasher Investigator Isaac Delke Investigator Michael Miller Investigator Kristi Stowers Investigator Elizabeth Martino Laboratory Technician/Technologist Diane Swindell Research Assistant Geraldine (Geri) Thomas Research Nurse Mobeen Rathore Site Leader Margot Althuis-Brown Study Coordinator Indira Becerrit Study Coordinator Doriana Boro Study Coordinator Barbara Millwood Study Coordinator Studies at this Site IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum. DAIDS Number 38609 Research Area Therapeutics Study Status Closed to Follow Up IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Therapeutics Study Status Enrolling IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status Open to Accrual IMPAACT 2046: UPLIFT Study DAIDS Number 39171 Research Area Brain and Mental Health Study Status Open to Accrual Pagination Previous page Prev Page 1 Current page 2
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum. DAIDS Number 38609 Research Area Therapeutics Study Status Closed to Follow Up
IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Therapeutics Study Status Enrolling
IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status Open to Accrual
IMPAACT 2046: UPLIFT Study DAIDS Number 39171 Research Area Brain and Mental Health Study Status Open to Accrual